Bringing the very best science and medicine to our best equine friends
August 2015

Kindred Biosciences Announces Second Quarter 2015 Financial Results

San Francisco, CA (August 10, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the second quarter ended June 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. Some of the recent highlights include: Completion of enrollment in SentiKind™ pivotal study. The pivotal field trial of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, recently completed enrollment and the Company plans to report topline results before the end of this …

Continue Reading